
Where the Money Moved
Ollin Biosciences Raises $330M Series B to Advance Next-Generation Eye Disease Therapies
Ollin Biosciences raised a $330M Series B co-led by TCGX and ARCH Venture Partners to advance OLN324 and OLN102 for retinal and thyroid eye diseases.
Jesse Landry

























































